6- isopropyl- 3- (4- (4- chlorobenzenesulfonylamino)butyl)azulene- 1- sulfonic acid sodium salt

structure given in first source; a prostaglandin endoperoxide receptor antagonist; RN given refers to the mono-sodium salt; RN for parent cpd not available 4/93

Also Known As:

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Auchampach, John A: 1 article (03/2003)
2.	Ge, Zhi-Dong: 1 article (03/2003)
3.	Gross, Garrett J: 1 article (03/2003)
4.	Piper, Galen M: 1 article (03/2003)

Related Diseases

1.	Myocardial Ischemia (Ischemic Heart Diseases) 03/01/2003 - "The purpose of the current study was to compare the efficacy of two structurally unrelated thromboxane A (TXA ) receptor antagonists, KT2-962 and daltroban (BM 13.505), in a dog model of myocardial ischemia/reperfusion injury. "
2.	Reperfusion Injury 03/01/2003 - "The purpose of the current study was to compare the efficacy of two structurally unrelated thromboxane A (TXA ) receptor antagonists, KT2-962 and daltroban (BM 13.505), in a dog model of myocardial ischemia/reperfusion injury. "
3.	Coronary Occlusion 03/01/2003 - "Vehicle, KT2-962 (10 mg/kg), or daltroban (10 mg/kg) were administered as intravenous boluses 10 minutes before coronary occlusion. "
4.	Ventricular Fibrillation 03/01/2003 - "However, administration of KT2-962, but not daltroban, significantly reduced the incidence of ventricular fibrillation during the ischemic period and significantly reduced myocardial infarct size expressed as a percentage of the risk region (approximately 40%). "
5.	Myocardial Infarction 03/01/2003 - "However, administration of KT2-962, but not daltroban, significantly reduced the incidence of ventricular fibrillation during the ischemic period and significantly reduced myocardial infarct size expressed as a percentage of the risk region (approximately 40%). "

Related Drugs and Biologics

1.	Thromboxanes
2.	daltroban